DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy Bioassay Services Market by Type of Therapy, Therapeutic Area, Scale of Operation and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report's publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages.
Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services.
Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.
The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays.
In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.
Companies Mentioned
- 4D Molecular Therapeutics
- AavantiBio
- aaVective
- AAVogen
- AbbVie
- AbClon
- Abeona Therapeutics
- Absorption Systems
- Adaptimmune Therapeutics
- Adelson Medical Research Foundation (AMRF)
- Adicet Bio
- Advanced Cell Diagnostics
- Advantagene
- Advaxis
- Adverum Biotechnologies
- Aeon Therapeutics
- Affinia Therapeutics
- AffyImmune Therapeutics
- Agency for Science, Technology and Research (A*STAR)
- AgenTus Therapeutics
- AGTC
- AIT Bioscience
- Akouos
- Allergan
- Allogene Therapeutics
- AlphaVax
- Altasciences
- Altheia Science
- Altor Bioscience
- Amarna Therapeutics
- Ambulero
- American Gene Technologies
- Amgen
- Amicus Therapeutics
- AnaBioTec
- Anaeropharma Science
- AnGes
- Angionetics
- AnHui Medical University (AHMU)
- ApolloBio
- Applied StemCell
- Arbele
- Aruvant Sciences
- ASC Therapeutics
- Asklepios BioPharmaceutical (AskBio)
- Atara Biotherapeutics
- Atsena Therapeutics
- Aurigon
- Aurora Biopharma
- Avance Biosciences
- And Many More Companies!
Key Questions Answered
- Who are the leading services providers offering bioassay services related to cell and gene therapies?
- What is the relative competitiveness of different cell and gene therapy bioassay service providers?
- Which is the commonly offered bioanalytical service (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) related to cell and gene therapy?
- What are the key trends within the cell and gene therapy bioassay service providers market?
- What kind of initiatives are being taken by stakeholders engaged in this domain?
- Which players are likely to partner with cell and gene therapy bioassay service providers?
- How is the current and future opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to teleradiology services market?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
8. MARKET TREND ANALYSIS
9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS
10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES
11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS
12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. CONCLUSION
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/3rvbdt
